Newswise — Glorious sunshine greeted 3,700 visitors in the Austrian capital city of Vienna when they gathered from 11-16 July for the 12th International Conference on Alzheimer's Disease (ICAD), hosted by the Alzheimer's Association.
The scientific program started with humbling reports of the failure—abject and otherwise—of the latest round of clinical trials. The program continued with confirmatory studies on the ability of exercise, a heart-healthy diet, and modest drinking while one is cognitively healthy, to modify one's risk of cognitive decline somewhat. This is an important life message people should take to heart, but it is not the kind of news close followers of the field are looking for. But then the last morning—when many had departed, the exhibit hall was emptied out, and the press room had closed up shop—featured within the space of three hours arguably the biggest news in AD genetics research in the past decade. Three independent genomewide association studies, one being the largest performed to date on some 4,000 cases, together reported three new genes for late-onset AD.
For details, read the reports by Alzheimer Research Forum managing editor Gabrielle Stobel.
New Genes, Anyone? ICAD Saves Best for Last
http://www.alzforum.org/new/detail.asp?id=2197
In Genetics, Bigger Is Better—Data Sharing Nets Three New Hits
http://www.alzforum.org/new/detail.asp?id=2199
New Shoot Among Ashes of Drug Trials
http://www.alzforum.org/new/detail.asp?id=2202
What's New With Methylene Blue?
http://www.alzforum.org/new/detail.asp?id=2203
New Tack to See Amyloid Oligomers in Body Fluids
http://www.alzforum.org/new/detail.asp?id=2206
Can a D-Peptide Turn Tiger Into Pussycat?
http://www.alzforum.org/new/detail.asp?id=2207
The Alzheimer Research Forum (www.alzforum.org), founded in 1996, is the web's most dynamic scientific community dedicated to understanding Alzheimer disease and related disorders. Access to the web site is free to all. The Forum's editorial priorities are as diverse as the needs of the research community. The web site reports on the latest scientific findings, from basic research to clinical trials; creates and maintains public databases of essential research data and reagents; and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease.
The ARF team of professional science writers and editors, information technology experts, web developers and producers all work closely with its distinguished and diverse Advisory Board to ensure a high quality of information and services. The Alzheimer Research Forum is an independent nonprofit organization supported by grants and individual donations. The web site does not endorse any specific product or scientific approach.
RSS